ClinicalTrials.gg
Active, not recruitingNCT05137171Updated Oct 22, 2026

AK105 Combined With Anlotinib in Patients With Cervical Cancer

A Phase 2 interventional study of AK105 and anlotinib in Cervical Cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Active, not recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now Active, not recruitingFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 458 studies in Uterine Cervical Neoplasms with a site in China — 208 open to participants now, 243 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
256th of 363
36 · median 89
Started
2022
with 61 others
Phase 2
139 of 458
73 open now
Primary completion
2025-07
later than 68 of 242 live
Registered
200th of 458
by date

Among the 458 studies in Uterine Cervical Neoplasms with a site in China, this one is the 256th largest by planned enrollment of the 363 interventional ones that give a count, is one of 62 that started in 2022, is one of 139 in phase 2, reaches primary completion later than 68 of the 242 other live ones, and was the 200th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

208 of the 458 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

203 more — sign in →

All 208 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 458 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of AK105 (anti-PD-1 mab) combined with Anlotinib Hydrochloride in the treatment of persistent, recurrent and metastatic cervical cancer.

Read the detailed description

This is an open-label, single-arm, multicenter phase II clinical trial evaluating the efficacy and safety of AK105 (penpulimab, 200 mg IV Q3W) combined with anlotinib (12 mg orally, 2 weeks on/1 week off, Q3W) as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer (histologic types include squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma). Eligible patients have not received prior systemic therapy for recurrent or metastatic disease. Imaging assessments are performed every 3 cycles. All patients will receive treatment until radiographic progression, unacceptable toxicity, investigator or patient decision to withdraw, or non-adherence to treatment or trial procedures.

03

Conditions studied

  • Cervical Cancer

Keywords

  • AK105,anlotinib,recurrent,metastatic
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily participated in the study and signed ;
  2. Age between 18 and 75;
  3. Agreed to detect the expression status of biomarker;
  4. score is 0 or 1, and the expected survival time is not less than 3 months;
  5. confirmed recurrent or squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma with documented disease progression. Note that histological confirmation of the original primary tumor is required by pathological reports;
  6. Patients with recurrent or metastatic cervical cancer who had received at least once platinum-based systemic chemotherapy in the curative setting were included;
  7. The patient is not suitable for local treatment (surgery or radiotherapy cannot be performed);
  8. Patients with as defined in RECIST1.1 criteria;
  9. The main organs function is well, and the laboratory test indexes meet the following requirements:(1) Routine blood test (no blood transfusion or hematopoietic stimulating factor was used within 7 days before screening) :① (HB) ≥ 90g/L;② (ANC) ≥1.5×109/L;③ (PLT) ≥ 80×109/L;(2) Blood biochemical test (no blood transfusion or albumin within 7 days before screening) :① and AST ≤2.5 × (liver/bone metastasis ≤5 × ULN;Bone metastases ≤5 ULN);② Serum total (TBIL) ≤1.5 × ULN;③ Serum Cr≤1.5×ULN or ≥60 mL /min;(3) Coagulation function test:① Activated partial thrombin time (), international standardized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN;② Doppler ultrasound assessment: (LVE F)≥ 50%;
  10. Any toxic side effects of previous chemotherapy have been recovered to ≤CTCAE1 or baseline level;
  11. The patient has the ability to take medication orally;
  12. Women of reproductive age must agree to use a highly effective method of during the study period and for 6 months after the last administration of the study drug;Negative serum or urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects;

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history or signs of ;
  2. Prior use of bevacizumab, antiangiogenic drugs and other antiangiogenic drugs;
  3. Received anti-tumor monoclonal antibody treatment within 4 weeks before enrollment; Had previously received other /PD-L1 antibodies and anti-CTLA-4 (cytotoxic T-lymphocyte associated antigen-4) therapy.
  4. Patients were receiving or systemic hormone therapy for immunosuppression (dose > 10mg/ day of prednisone or other equivalent hormone) and were still using 2 weeks prior to enrollment
  5. Participate in other clinical trials or complete other clinical trials within 4 weeks;
  6. Abnormal coagulation function ( > 2.0, PT > 16s), bleeding tendency or receiving thrombolytic or anticoagulant therapy;
  7. Failed to recover from adverse events (except hair loss) after prior medication use;
  8. The patient has any active disease or a history of autoimmune disease;
  9. Clinical symptoms or diseases of the heart that are not well controlled;
  10. Congenital or acquired immune deficiency;
  11. Received chemotherapy, targeted and radiotherapy within 2 weeks before enrollment;
  12. Concomitant diseases/History:(1) hemoptysis occurred within 3 months before enrollment (hemoptysis > 50ml per day);Or bleeding symptoms of significant clinical significance or a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occultation and above, or suffering from vasculitis, etc.;(2) Arteriovenous thrombosis events occurred within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except those who had been cured after intravenous catheterization due to chemotherapy) and pulmonary embolism, etc.;(3) hypertension, which cannot be well controlled by antihypertensive drug therapy (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg);During the first 6 months of randomization, myocardial infarction, severe/unstable angina, grade 2 or higher cardiac dysfunction, clinically significant ventricular arrhythmias or ventricular arrhythmias, and symptomatic congestive heart failure;(4) Interstitial lung disease, non-infectious pneumonia or uncontrollable systemic diseases (e.g., diabetes, pulmonary fibrosis and acute pneumonia);(5) Renal insufficiency: urine protein ≥ ++ indicated by routine urine examination, or confirmed 24-hour urine protein level ≥1.0g; (6) History of vaccination within 28 days prior to initial study administration or expected live attenuated vaccine vaccination during study period;(7) (HIV) infection or known acquired immunodeficiency syndrome (AIDS);Active hepatitis (, defined as HBV-DNA ≥ 500 IU/ mL;, defined as hcV-RNA higher than the lower limit of assay) or co-infection with hepatitis B and c;(8) Severe infection, including but not limited to bacteremia and severe pneumonia requiring hospitalization, occurred within 4 weeks before the first administration;Active infection with grade ≥2 requiring systemic antibiotic treatment within 2 weeks prior to initial administration, or fever of unknown origin >38.5°C during screening/prior to initial administration (as determined by the investigator, fever due to tumor can be included);Evidence of active tuberculosis infection within 1 year before administration;(9) Have been diagnosed with any other malignant tumor within 3 years prior to entry into the study;(10) Major surgery performed within 28 days before enrollment (tissue and peripheral venipuncture placement of central venous catheter [PICC] required for diagnosis are permitted);
  13. Subjects who have received or are planning to receive bone marrow transplantation or solid organ transplantation;
  14. Peripheral neuropathy ≥ grade 2;Patients with active brain metastases, cancerous meningitis, spinal cord compression, or diseases of the brain or pia meningeal found by imaging CT or MRI examination at the time of screening (patients with brain metastases who had completed treatment 14 days before enrollment and had stable symptoms could be enrolled, but were confirmed to have no symptoms of cerebral hemorrhage by craniocerebral MRI, CT or venography evaluation);
  15. There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea, and presence of clinically significant intestinal obstruction.
  16. interval > 470 msec;If a patient has a prolonged QT interval, but the investigator assessed the cause of the prolonged QT interval as pacemaker (and no other cardiac abnormalities), discussion with other study physicians will be required to determine whether the patient is eligible for inclusion.
  17. Known allergic to pharmaceutical ingredients;
  18. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study period.
  19. Patients with other serious physical or mental disorders or abnormal laboratory tests that may increase the risk of study participation or interfere with study results, and who are considered unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    AK105 and anlortinib

    AK105 200mg iv q3w;anlotinib 12mg 2w on/1w off po qd;21 days as a cycle until PD,intolerable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.

    Drug: AK105 and anlotinib

Interventions

  • DrugAK105 and anlotinib

    Drug pages: PenpulimabStudies of PenpulimabPenpulimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AnlotinibStudies of AnlotinibAnlotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.

    Also known as: penpulimab and anlotinib

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate

    Time frame: up to 24 months

Secondary outcomes

  1. PFS

    progression-free survival

    Time frame: up to 24 months

  2. OS

    overall survival

    Time frame: up to 24 months

07

Study locations

2 sites
  • Henan Polytechnic University Affiliated Hospital/Jiaozuo Second People's Hospital
    Jiaozuo, Henan 454000, China
  • Luoyang Central Hospital
    Luoyang, Henan 471000, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2025, 37 months.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 37 months is below that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Mar 2022 → May 2022, primary completion Mar 2024 → Jul 2025 and completion Sep 2024 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 30, 2021
StartActual
May 2, 2022was Mar 2022
Primary completionActual
Jul 1, 2025was Mar 2024
CompletionEst.
Dec 31, 2027was Sep 2024
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Oct 22, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Henan Polytechnic University Affiliated Hospital/Jiaozuo Second People's Hospital · Jiaozuo, China
  • Luoyang Central Hospital · Luoyang, China
Oct 22, 2026
Start date
Mar 1, 2022→May 2, 2022 (actual)
Oct 22, 2026
Primary completion
Mar 1, 2024→Jul 1, 2025 (actual)
Oct 22, 2026
Study completion
Sep 1, 2024→Dec 31, 2027
Oct 22, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with recurrent or metastatic cervical cancer who had received at least once platinum-based systemic chemotherapy in the curative setting were included;
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Active, not recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Henan Polytechnic University Affiliated Hospital/Jiaozuo Second People's Hospital · Jiaozuo, China
    • Luoyang Central Hospital · Luoyang, China
    Start date Mar 1, 2022→May 2, 2022 (now actual)
    Primary completion Mar 1, 2024→Jul 1, 2025 (now actual)
    Study completion Sep 1, 2024→Dec 31, 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with recurrent or metastatic cervical cancer who had received at least once platinum-based systemic chemotherapy in the curative setting were included;
    + 5 other changes: index terms, identifiers, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05137171
Responsible party
Ruixia Guo (Director, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
Nov 30, 2021
Start date
May 2, 2022
Primary completion
Jul 1, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Ruixia Guo, Director
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Penpulimab · Anlotinib

Start the discussion